Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Nuvo Research Offers Low-Risk With Big Upside

(Editor's Note: Investors should be mindful of the risks of transacting in illiquid securities such as NRIFF. Improved liquidity can be found on the Toronto Stock Exchange under NRI.TO.)

Nuvo Research, Inc. (NRI.TO) (OTCPK:NRIFF) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The company has two separate business units: Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four marketed products and a pipeline of products at various stages of development along with four topical and transdermal drug delivery platforms. The Immunology Group has two commercialized products, a developmental program for the treatment of allergic rhinitis, and a potential immune modulating platform.

TPT commercial products include four FDA-approved

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details